Physician profile
Frank Yeh
NPI 1710102959
$9,904.38
in general payments reported to CMS, 2019-2025
33 companies · $699 in 2025
The $699 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,173 · 2020: $948 · 2021: $1,733 · 2022: $2,002 · 2023: $1,722 · 2024: $628 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,949 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,948.89 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,091.64 | 2019-2024 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,177.82 | 2019-2024 | Xifaxan |
| Janssen Biotech, INC. | $970.94 | 2019-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $885.10 | 2019-2024 | Eohilia, Entyvio, Gattex |
| Nestle Healthcare Nutrition INC. | $826.04 | 2020-2023 | |
| Celgene Corporation | $772.85 | 2021-2023 | Zeposia |
| Pfizer INC. | $407.03 | 2019-2024 | |
| Gilead Sciences, INC. | $345.48 | 2019-2021 | |
| Madrigal Pharmaceuticals | $319.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $319.61 | 2025 | Wegovy |
| Lilly USA, LLC | $239.77 | 2024-2025 | Omvoh, Zepbound |
| Intercept Pharmaceuticals, INC. | $207.53 | 2019-2023 | Ocaliva |
| Braintree Laboratories, INC. | $200.00 | 2019-2023 | Sutab |
| Daiichi Sankyo INC. | $156.41 | 2019-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $131.10 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $122.62 | 2019 | |
| Boston Scientific Corporation | $119.04 | 2019-2022 | |
| Genzyme Corporation | $91.34 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $72.52 | 2019 | |
| Amgen INC. | $63.91 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $49.13 | 2022-2023 | Dupixent |
| Aimmune Therapeutics, INC. | $38.14 | 2023 | |
| Ironwood Pharmaceuticals, INC | $36.59 | 2019-2020 | |
| Allergan, INC. | $36.27 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $34.64 | 2023 | Idacio |
| Digestive Care, INC. | $31.53 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.30 | 2024 | |
| Qol Medical, LLC | $26.04 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $23.02 | 2025 | Iqirvo |
| Exact Sciences Corporation | $22.68 | 2023 | Cologuard Collection Kit |
| Apollo Endosurgery US INC | $19.69 | 2019 | |
| Capsovision, INC. | $19.44 | 2023 | Capsocam Plus |
| Ucb, INC. | $17.40 | 2023 | Cimzia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Yeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.